-
Mashup Score: 1Cytogenetic Analysis Reveals Lower Risk Profile in African American Patients With MDS | Blood Cancers Today - 9 day(s) ago
The rate of abnormal cytogenetics among African American patients with MDS is comparable to or lower than the general population.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Jamie Koprivnikar, MD, Talks COMMANDS Trial, Luspatercept Dosing | Blood Cancers Today - 9 day(s) ago
More patients treated with luspatercept had improvement or resolution of neutropenia and thrombocytopenia, she said.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🗨️ Jamie Koprivnikar, MD, of @HMHNewJersey @JTCancerCenter, discusses her thoughts on the COMMANDS trial of luspatercept versus epoetin alfa in patients with #MDS! 📺 Watch here: https://t.co/52baQtJDkN https://t.co/Z3RMrddikh
-
-
Mashup Score: 7Investigational Studies in MDS: Exploring Promising Therapies - 10 day(s) ago
David Sallman, MD, discussed the challenges and new studies of high-risk myelodysplastic syndrome therapies.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In an interview with Targeted Oncology, David Sallman, MD, discussed the challenges and new studies of high-risk myelodysplastic syndrome therapies. #MDS @MoffittNews https://t.co/ykbSitHRLB https://t.co/lnnKF2Stlu
-
-
Mashup Score: 0Future Perspective on Anemia Treatment in LR-MDS - 11 day(s) ago
Saeed Sadeghi, MD, explores the future treatment landscape for anemia in lower-risk myelodysplastic syndromes (LR-MDS), discussing the impact of emerging therapies on erythropoietin-stimulating agents (ESAs), identifying unmet needs in anemia management, and sharing clinical insights for community oncologists.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In this video, Saeed Sadeghi, MD, explores the future treatment landscape for anemia in lower-risk myelodysplastic syndromes. #MDS | @SaeedokMD @UCLAHealth https://t.co/K6WqOqk0at
-
-
Mashup Score: 8
Researchers utilized a data-driven approach to resolve discrepancies between the WHO and ICC classification systems for MDS, which can create inconsistencies in a clinical setting.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🤝 Researchers have utilized a data-driven approach to resolve discrepancies in the @WHO and ICC 2022 classifications of #MDS. 📝 Read more from the consensus paper led by @Ramikomrokji, of @MoffittNews, and published in @TheLancetHaem. ➡️ https://t.co/lr9hG31mNV https://t.co/GEIyUHhAMZ
-
-
Mashup Score: 1Genomic Profiling Identifies MDS Subgroups Associated With Clinical Outcomes | Blood Cancers Today - 11 day(s) ago
Researchers performed genomic profiling on patients with MDS and identified 18 subtypes associated with distinct clinical phenotypes and outcomes.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🧬 Genomic profiling identifies molecular subgroups of #MDS associated with distinct clinical phenotypes and outcomes. 📝 Read more from the study led by @Elsa2Bernard, of @CompOncMSK and @GustaveRoussy, and published in @BloodJournal. ➡️ https://t.co/IkHvLxKj4v https://t.co/d52oTLAFJ0
-
-
Mashup Score: 1Artificial Intelligence-Based Flow Cytometry Accurately Classifies, Prognosticates MDS | Blood Cancers Today - 12 day(s) ago
The researchers found a perfect correlation between the AI-based multiparametric flow cytometry score and the IPSS-M.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
📝 Researchers from @HopSaintLouis and @CHUAmiens have developed an artificial-intelligence-based multiparametric flow cytometry score that can accurately classify and risk stratify #MDS compared to the 2022 IPSS-M, as published in @Haematologica. ➡️ https://t.co/QNwMuWeX3w https://t.co/pDo4HDNntW
-
-
Mashup Score: 3
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
What is the impact of luspatercept on cell lineages in #MDS? A roundtable discussion with Jamile Shammo, @MdSwoboda, Saeed Sadeghi, and @benton_leukemia lends insight! 📺 Watch here: https://t.co/FGe5FkthZp https://t.co/xXaDBf0Q8n
-
-
Mashup Score: 2Current Approach to Treating Anemia in LR-MDS - 17 day(s) ago
Saeed Sadeghi, MD, shares his current approach to treating anemia in lower-risk myelodysplastic syndromes (LR-MDS), detailing when to choose erythropoiesis-stimulating agents (ESAs) for first-line treatment, conditions for switching therapies, and factors influencing the decision to use luspatercept as a first-line option, including considerations for dose escalation.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Saeed Sadeghi, MD, shares his current approach to treating anemia in lower-risk myelodysplastic syndromes. #MDS | @SaeedokMD @UCLAHealth https://t.co/achGQ8hlle
-
-
Mashup Score: 9
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
In this roundtable discussion, Drs. Jamile Shammo @MdSwoboda, Saeed Sadeghi, and @benton_leukemia share what to know about optimal luspatercept use in lower-risk #MDS. 📺 Watch here! https://t.co/T5ZajkZWe4 https://t.co/k0brV31jmZ
-
The frequency of abnormal cytogenetics among African American patients with #MDS is comparable to or lower than the general population. Read more from the study led by @KaurNavneetMD of @namccares. ➡️ https://t.co/mXL0YPClo0 https://t.co/9v0Maqd31q